Home
NewsNewsINVO Fertility acquires Family Beginnings in a strategic move to expand its U.S. footprint and strengthen patient-centered reproductive care. The acquisition integrates advanced IVF and INVOcell services, reinforces operational growth, and ensures leadership continuity under Dr. James Donahue within INVO’s expanding clinical network.
Feb. 19, 2026 – INVO Fertility, a leader in expanding access to assisted reproductive technology, announced the successful closing of its acquisition of Family Beginnings, P.C. This finalization marks the completion of the strategic transaction first detailed in the company's previous announcement.
The acquisition of the Indiana-based clinic was executed according to the terms of the definitive purchase agreement, with INVO acquiring the non-clinical assets for a combined purchase price of $760,000, $1 million in revenue, and $0.2 million in net income for the nine months ending September 30, 2025. This performance accounted for nearly 18% of INVO’s total clinic revenue during that period.
INVO Fertility acquires Family Beginnings with a clear focus on maintaining the high standard of personalized, patient-first care for which the clinic is known. To ensure a seamless transition and continuity of care, James Donahue, M.D., the clinic’s REI and lab director, has entered into a multi-year agreement to continue leading operations. Dr. Donahue, recently recognized as a 2026 Castle Connolly Top Doctor, brings decades of expertise to the INVO network.
The clinic offers a comprehensive suite of reproductive services, including traditional IVF, ovulation induction, and intrauterine insemination. Notably, Family Beginnings was an early adopter of INVO’s proprietary INVOcell solution, an intravaginal culture (IVC) procedure that allows fertilization to take place in vivo within the woman’s body.
Steve Shum, CEO of INVO Fertility, highlighted the strategic importance of the deal, stating that it expands the company’s geographic footprint while advancing its mission to provide affordable, high-quality fertility care. The closing follows a period of "meaningful progress" for the company, as INVO continues to execute a growth strategy centered on both organic initiatives and targeted acquisitions.
By integrating Family Beginnings into its growing network of operational U.S. clinics, INVO Fertility aims to leverage its broader clinical resources and ongoing investment in advanced technologies to support patients through the emotional journey of reproductive treatment.
Legacy, North America's leading digital male fertility clinic, has secured New York State CLEP approval for both its semen analysis and DNA fragmentation test – the only mandatory pre-market laboratory review programme in the United States. The approvals confirm clinical-grade validity for at-home samples, extending access to New York patients without a clinic visit.
From 1 July 2026, South Australia's Fertility Treatment Rebate Scheme provides eligible residents with a $250 rebate for pre-treatment testing and a $2,000 rebate for up to two fertility treatment cycles. Backed by an $18.5 million, four-year government commitment, the scheme directly addresses the financial barriers preventing South Australians from accessing fertility care.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
